CJC-1295 with DAC
Also called CJC-1295, CJC-1295 DAC, CJC 1295 DAC, DAC-GRF, DAC:GRF.
CJC-1295 with DAC has no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
Two short randomized placebo-controlled trials in healthy adults aged 21 to 61 found sustained increases in GH and IGF-1 after subcutaneous CJC-1295 with DAC.
Limits: These early pharmacology studies measured biomarkers, not fat loss, strength, sleep, or longevity benefits. FDA identifies the tested active moiety as DAC-containing but the salt form as unspecified. Results do not apply to MOD GRF or no-DAC products.
Regulatory status
United States
As of November 6, 2026, no CJC-1295 product is FDA-approved for any indication. FDA distinguishes DAC-containing and non-DAC active moieties. Compounding review does not constitute drug approval.